InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.170
-0.070 (-5.65%)
At close: Nov 13, 2026, 4:00 PM EST
1.140
-0.030 (-2.56%)
After-hours: Nov 13, 2026, 7:30 PM EST
InflaRx Revenue
InflaRx had revenue of -33.93K EUR in the twelve months ending September 30, 2026. In the year 2025, InflaRx had annual revenue of 29.33K, down -82.31%. That makes InflaRx the 48,051st largest company in the world by revenue and 7,379th in the United States.
Revenue (ttm)
-33.93K EUR
Revenue Growth
-82.31%
P/S Ratio
n/a
Revenue / Employee
-522 EUR
Employees
65
Market Cap
172.42M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Invivyd | 58.37M |
| Sutro Biopharma | 45.11M |
| Atrium Therapeutics | 38.82M |
| Zentalis Pharmaceuticals | 26.87M |
| Alpha Cognition | 20.20M |
| Whitehawk Therapeutics | 7.15M |
| Sol-Gel Technologies | 1.44M |
IFRX News
- 5 days ago - InflaRx Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan - GlobeNewsWire
- 12 days ago - InflaRx sees up to $2B peak sales for izicopan in vasculitis, plans 2027 trials - TheFly
- 12 days ago - InflaRx Transcript: CMD 2026 - Transcripts
- 12 days ago - InflaRx Press release: FY 2026 - Filings
- 12 days ago - InflaRx Slides: FY 2026 - Filings
- 12 days ago - InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day - GlobeNewsWire
- 19 days ago - InflaRx Announces November Investor Events - GlobeNewsWire